Evaluation of de-escalation of anti-TNF-α therapy in inflammatory bowel disease

被引：3

作者：

Sedano Munoz, Rocio ^{[1
]}

Quera Pino, Rodrigo ^{[2
,3
]}

Lubascher Correa, Jaime ^{[2
,3
]}

Pizarro Jofre, Gonzalo ^{[2
,3
]}

Simian Marin, Daniela ^{[2
,4
]}

机构：

[1] Hosp Clin Univ Chile, Serv Gastroenterol, Santiago, Chile

[2] Clin Las Condes, Programa Enfermedad Inflamatoria Intestinal, Santiago, Chile

[3] Clin Las Condes, Dept Gastroenterol, Santiago, Chile

[4] Clin Las Condes, Subdirecc Acad, Santiago, Chile

来源：

GASTROENTEROLOGIA Y HEPATOLOGIA | 2019年 / 42卷 / 02期

关键词：

Inflammatory bowel disease; Anti-tumour necrosis factor; Infliximab; Adalimumab; Treatment withdrawal; CROHNS-DISEASE; MAINTENANCE TREATMENT; CLINICAL REMISSION; INFLIXIMAB MAINTENANCE; COMBINATION THERAPY; ULCERATIVE-COLITIS; LONG; DISCONTINUATION; ADALIMUMAB; WITHDRAWAL;

D O I：

10.1016/j.gastrohep.2018.10.010

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Anti-tumour necrosis factor a therapy in inflammatory bowel disease has been shown to be effective in clinical practice. After more than a decade using these therapies the question arises about whether there is an appropriate time to suspend these therapies, and how this should be done. This review aims to evaluate the current evidence on these topics concerning anti-tumour necrosis factor a therapies, and eventually identify conditions and subgroups of patients that could potentially be candidates for withdrawal. (C) 2018 Elsevier Espana, S.L.U. All rights reserved.

引用

页码：133 / 140

页数：8

共 50 条

[21] Systematic review: antibodies and anti-TNF-α levels in inflammatory bowel disease
Chaparro, M.
Guerra, I.
Munoz-Linares, P.
Gisbert, J. P.
[J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (09) : 971 - 986
[22] Letter: number of treatments with anti-TNF-α and reoperations in inflammatory bowel disease
Norgard, B. M.
Nielsen, J.
Kjeldsen, J.
Qvist, N.
[J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 37 (10) : 1028 - 1029
[23] Anti-TNF-α Therapy in Late Pregnancy and the Risk of Adverse Birth Outcomes in Women with Inflammatory Bowel Disease
Kammerlander, Heidi
Nielsen, Jan
Kjeldsen, Jens
Knudsen, Torben
Friedman, Sonia
Norgard, Bente
[J]. INFLAMMATORY BOWEL DISEASES, 2017, 23 : S17 - S17
[24] Combination treatment with vedolizumab and anti-TNF-α in inflammatory bowel disease: safety data
Buer, L.
Hoivik, M. L.
Medhus, A. W.
Moum, B.
[J]. JOURNAL OF CROHNS & COLITIS, 2017, 11 : S341 - S342
[25] Anti-TNF-α Agents in Inflammatory Bowel Disease and Course of COVID-19
Tursi, Antonio
Vetrone, Lorenzo Maria
Papa, Alfredo
[J]. INFLAMMATORY BOWEL DISEASES, 2020, 26 (07) : E73 - E73
[26] Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series
Buer, Lydia C. T.
Hoivik, Marte L.
Warren, David J.
Medhus, Asle W.
Moum, Bjorn A.
[J]. INFLAMMATORY BOWEL DISEASES, 2018, 24 (05) : 997 - 1004
[27] De-escalation of biological therapy in Inflammatory bowel disease (IBD) and outcomes at week 52: a single centre experience
Al-Talib, Ismaeel
Iqbal, Majid
Shaheen, Sirah
Shingadia, Maya
Slater, Jayne
King, Dominic
Rattehalli, Deepa
De Silva, Shanika
[J]. GUT, 2023, 72 (SUPPL_2) : A79 - A79
[28] Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease
Paul, S.
Roblin, X.
Peyrin-Biroulet, L.
[J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (07) : 939 - 940
[29] Anti-TNF combination therapy in inflammatory bowel disease: de novo or selective?
Macaluso, Fabio S.
Orlando, Ambrogio
[J]. MINERVA GASTROENTEROLOGICA E DIETOLOGICA, 2019, 65 (04) : 291 - 297
[30] Myeloproliferative Disorder in Patients with Inflammatory Bowel Disease on Anti-TNF-α Therapy: Report of Two Cases and Review of the Literature
Fischer, Monika
Helper, Debra
Chiorean, Michael
[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S480 - S481

← 1 2 3 4 5 →